Buntanetap mesylate (formerly ANVS401/PD-01) is an oral small molecule drug being developed for the treatment of Alzheimer's disease and Parkinson's disease. This Phase 3 clinical trial (NCT06709014) is evaluating the safety and efficacy of Buntanetap in participants with early Alzheimer's disease["@novel2024"].
The trial is sponsored by Annovis Bio Inc. and represents a significant advancement in developing disease-modifying therapies for neurodegenerative conditions. Buntanetap targets multiple pathological pathways implicated in Alzheimer's disease pathogenesis, including amyloid processing, tau phosphorylation, neuroinflammation, and synaptic dysfunction["@mechanismdriven2024"].
...
Buntanetap for Early Alzheimer's Disease (NCT06709014)
Overview
Mermaid diagram (expand to render)
Buntanetap mesylate (formerly ANVS401/PD-01) is an oral small molecule drug being developed for the treatment of Alzheimer's disease and Parkinson's disease. This Phase 3 clinical trial (NCT06709014) is evaluating the safety and efficacy of Buntanetap in participants with early Alzheimer's disease["@novel2024"].
The trial is sponsored by Annovis Bio Inc. and represents a significant advancement in developing disease-modifying therapies for neurodegenerative conditions. Buntanetap targets multiple pathological pathways implicated in Alzheimer's disease pathogenesis, including amyloid processing, tau phosphorylation, neuroinflammation, and synaptic dysfunction["@mechanismdriven2024"].
Trial Details
| Parameter | Value | |-----------|-------| | NCT Number | NCT06709014 | | Phase | Phase 3 | | Status | RECRUITING | | Sponsor | Annovis Bio Inc. | | Enrollment | 760 participants (estimated) | | Enrollment Type | ESTIMATED | | Study Type | INTERVENTIONAL | | Start Date | February 4, 2025 | | Completion Date | June 1, 2028 | | Last Updated | January 30, 2026 |
Conditions Studied
Early Alzheimer's Disease - Participants with mild cognitive impairment or mild dementia due to AD
Therapeutic Target: Buntanetap Mechanism
Multi-Target Approach
Buntanetap represents a novel approach to Alzheimer's disease therapy by targeting multiple pathological mechanisms simultaneously[@buntanetapmech]:
Alpha-Synuclein Aggregation Inhibition: While primarily associated with Parkinson's disease, alpha-synuclein pathology is increasingly recognized in AD, particularly in the subtype of AD with Lewy body co-pathology.
Amyloid-Beta Processing: Buntanetap affects APP (amyloid precursor protein) processing to reduce amyloid-beta production through modulation of beta-secretase (BACE1) activity.
Tau Phosphorylation: The drug reduces tau hyperphosphorylation through inhibition of several kinases, potentially slowing neurofibrillary tangle formation.
Synaptic Protection: Buntanetap protects synaptic function by maintaining neurotransmitter release and synaptic plasticity[@synapse2024].
Mitochondrial Function: The drug supports mitochondrial integrity and function, addressing the energy deficit observed in AD brains[@mitochondria2024].
Molecular Target
Buntanetap acts as a small molecule inhibitor that:
Binds to amyloid precursor protein (APP) and alpha-synuclein
Prevents conformational changes that lead to protein aggregation
Reduces toxic oligomer formation
Enhances autophagy for clearance of protein aggregates
Scientific Background
Disease Context
Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 6.5 million Americans alone[@alzheimers2023]. The disease is characterized by:
Progressive cognitive decline
Memory loss, particularly for recent events
Functional impairment affecting daily activities
Behavioral and psychological symptoms
Pathologically, AD is characterized by:
Amyloid plaques: Extracellular deposits of amyloid-beta peptide
Neurofibrillary tangles: Intracellular aggregates of hyperphosphorylated tau
Synaptic loss: Reduction in synaptic connections
Neuronal death: Progressive loss of neurons in vulnerable brain regions
Amyloid Cascade Hypothesis
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis[@amyloid2023]. It proposes that:
Accumulation of amyloid-beta peptide triggers the disease process
Amyloid deposition leads to synaptic dysfunction
Tau hyperphosphorylation and neurofibrillary tangle formation follows
Neuronal death and cognitive decline result
However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches that address multiple pathological features simultaneously.
Aducanumab and lecanemab (anti-amyloid antibodies)
These treatments provide symptomatic benefit but do not halt disease progression. The field has increasingly focused on disease-modifying therapies that target underlying pathological mechanisms.
Study Design
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial[@clinical2023]. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations.
Key Design Features
Randomization: Participants are randomly assigned to treatment or placebo groups (1:1 ratio)
Double-blind: Neither participants nor investigators know the treatment assignment
Multi-center: The trial is conducted at multiple sites to ensure diverse patient representation
Controlled design: Comparison against placebo provides clear evidence of treatment effect
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease[@future2024]. The outcomes of this study may:
Advance therapeutic options: Successful results could lead to new treatment paradigms for patients with early AD